Foreign-Trade Zone (FTZ) 61, Notification of Proposed Production Activity; Boehringer Ingelheim Animal Health Puerto Rico LLC; (Animal Health Products); Barceloneta, Puerto Rico

Boehringer Ingelheim Animal Health Puerto Rico LLC, submitted a notification of proposed production activity to the FTZ Board (the Board) for its facility in Barceloneta, Puerto Rico within Subzone 61AC. The notification conforming to the requirements of the Board's regulations (15 CFR 400.22) was received on August 8, 2024.

Pursuant to 15 CFR 400.14(b), FTZ production activity would be limited to the specific foreign-status material/component and specific finished product described in the submitted notification (summarized below) and subsequently authorized by the Board. The benefits that may stem from conducting production activity under FTZ procedures are explained in the background section of the Board's website—accessible via www.trade.gov/​ftz. The proposed finished product and material/component would be added to the production authority that the Board previously approved for the operation, as reflected on the Board's website.

The proposed finished product is finished/packaged heartworm treatment chewable tablets for canines (duty-free).

The proposed foreign-status material/component is moxidectin (duty rate of 3.7%). The request indicates that the material/component is subject to duties under section 301 of the Trade Act of 1974 (section 301), depending on the country of origin. The applicable section 301 decisions require subject merchandise to be admitted to FTZs in privileged foreign status (19 CFR 146.41).

Public comment is invited from interested parties. Submissions shall be addressed to the Board's Executive Secretary and sent to: ftz@trade.gov. The closing period for their receipt is September 23, 2024.

A copy of the notification will be available for public inspection in the “Online FTZ Information System” section of the Board's website.

For further information, contact Kolade Osho at Kolade.Osho@trade.gov.